Integrated BioPharma, Inc. reports operating results and business updates for an OTCQX-traded manufacturer and distributor of vitamins, nutritional supplements and herbal products. The company’s recurring news centers on quarterly and fiscal-year revenue, operating income or loss, net income per share and performance in its Contract Manufacturing Segment.
Company updates also discuss customer concentration among the segment’s largest customers, customer-base diversification, and activity tied to its core manufacturing, warehousing, distribution, marketing and sales operations.
Integrated BioPharma, Inc. reports its financial results for the quarter ended March 31, 2024. Revenue remained stable between 2023 and 2024 at $13.1 million. The Company experienced an operating income increase from $44,000 to $0.4 million in the same period. However, for the nine-month period, revenue decreased slightly by 0.3% to $37.6 million, with an operating loss of $0.2 million compared to operating income of $41,000 in the previous year. Net income per share rose to $0.01 from $0.00 in the quarter ended March 31, 2023, but the nine-month period saw a net loss of $0.2 million compared to $74,000 in the previous year. The Company aims to reduce reliance on two major customers in the future.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
HILLSIDE, NJ / ACCESSWIRE / March 21, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) announced the passing of its Founder, Executive Chairman, and President, Edward G. Kay, at age 86. The Board expressed deep sadness over his loss, recognizing him as a visionary leader in the nutraceutical sector. The roles of president, director, and chairman are currently vacant as the Board plans to convene to appoint a new chairperson. Integrated BioPharma focuses on manufacturing and distributing vitamins and nutritional supplements. The Company warned that its future performance might be affected by the uncertainty following this leadership change.
Integrated BioPharma (INBP) reported financial results for the quarter ending December 31, 2022, with revenue of $12.3 million, down 15.6% from $14.6 million in 2021. The six-month revenue also declined to $24.6 million from $27.3 million, a 9.9% decrease. Operating income shifted to a loss of approximately $33,000 compared to $0.7 million income in the prior year. The company recorded a net loss of $55,000 or $0.00 per share, contrasting with a net income of $1.0 million or $0.04 per share for the same quarter in 2021. Key customers remained stable, contributing over 90% of total revenue. Issues like pandemic overstocking were cited as causes for revenue decline.
Integrated BioPharma, Inc. (OTCQX:INBP) reported a net loss of $35,000 for Q3 2022, contrasting with a net income of $516,000 in the same quarter last year. Revenue fell to $12.3 million, a 3.1% decrease from $12.8 million year-over-year. Operating income dropped significantly to $30,000 from $585,000 the previous year. The company attributes revenue decline to customer overstocking during the pandemic, despite offsetting some losses with increased sales to other customers.
Integrated BioPharma, Inc. (INBP) announced its financial results for the quarter and fiscal year ending June 30, 2022. Revenue decreased to $13.3 million for the quarter and $56.2 million for the fiscal year, down 22.2% and 11.6% year-over-year, respectively. Net income also fell, landing at $1.5 million ($0.05 per share) for the quarter and $3.8 million ($0.13 per share) for the year. The decline was attributed to increased safety stock and consumer demand changes during the pandemic, despite consistent revenue from major customers, which comprised 90% of total revenue.
Integrated BioPharma, Inc. (OTCQX:INBP) announced the resignation of Mr. Carl DeSantis as a Class I Director, with Mr. Damon DeSantis taking his place. The Co-CEOs expressed gratitude for Carl's service and optimism about Damon's experience in the nutraceutical sector, which they believe will be valuable for the Board. Damon has a notable history in the industry, including leadership roles at Celsius Holding, Inc. and Rexall Sundown. The company focuses on manufacturing and distributing nutritional products and acknowledges potential risks linked to market developments and ongoing uncertainties.